The Genetic Link between Parkinson’s Disease and the Kynurenine Pathway Is Still Missing

Nóra Török, 1 Rita Török, 1 Zoltán Szolnoki, 2 Ferenc Somogyvári, 3 Péter Klivényi, 1 and László Vécsei 1,4

1 Department of Neurology, Faculty of Medicine, Albert Szent-Györgyi Clinical Centre, University of Szeged, 6 Semmelweis Utca, Szeged 6725, Hungary
2 Department of Neurology and Cerebrovascular Diseases, Pándy Kálmán County Hospital, 1 Semmelweis Utca, Gyula 5700, Hungary
3 Department of Medical Microbiology and Immunobiology, University of Szeged, 10 Döm tér, Szeged 6725, Hungary
4 MTA-SZTE Neuroscience Research Group, 6 Semmelweis Utca, Szeged 6725, Hungary

Correspondence should be addressed to Péter Klivényi; klivenyi@nepsz.szote.u-szeged.hu

Received 3 December 2014; Revised 4 February 2015; Accepted 4 February 2015

Academic Editor: Heinz Reichmann

Copyright © 2015 Nóra Török et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Introduction

Parkinson’s disease (PD) is a chronic progressive neurodegenerative disease mostly among the elderly with characteristic pathological hallmarks; selective degeneration of the dopaminergic neurones in the substantia nigra pars compacta; and the presence of Lewy bodies.

The main mechanisms behind the aetiology and pathology of PD are oxidative stress, mitochondrial disturbances, protein aggregation, excitotoxicity, immunological mechanisms, and a genetic predisposition [1–7]. Recent studies also indicate the role of the altered tryptophan (Trp) metabolism in PD [8–10].

In the human brain, 95% of Trp is involved in the kynurenine pathway (KP) [11] (the rest 5% are involved in serotonin (5-hydroxytryptamine (5-HT)) pathway (SP) and the formation of proteins) (Figure 1). This enzymatic cascade is responsible for the synthesis of nicotinamide adenine dinucleotide (NAD) and NAD phosphate. Within the central nervous system, the infiltrating macrophages, activated microglia, and neurones are capable of the complete enzymatic cascade, whereas the astrocytes and oligodendrocytes lack kynurenine 3-monoxygenase (KMO) and indoleamine 2,3-dioxygenase (IDO) and are unable to produce the neurotoxic quinolinic acid (QUIN) [12]. The central metabolite of the KP is kynurenine (KYN), which is formed from Trp after two enzymatic steps (involving IDO/tryptophan 2,3-dioxygenase and formamidase). The kynurenic acid (KYNA) is synthesized after an irreversible transamination by kynurenine aminotransferases (KATs) from KYN. The other main branch of the cascade begins with formation of the neurotoxic 3-hydroxykynurenine (3-HK) by KMO. This enzyme,
situated in the outer membrane of the mitochondria [13], is responsible for the neurotoxic branch, the concentration of KYNA depending indirectly on the activity of KMO. Kynureinase converts 3-HK to another neurotoxic metabolite, QUIN. These two well-known neurotoxic intermediates of the KP are free radical generators, and 3-HK plays a role in immune processes, while QUIN is an NMDA receptor agonist [9].

In recent years, increasing evidence has emerged from an association between PD and the disruption of the KP and the SP. Lower 5-HT, KYN, and KYNA concentrations were measured in the frontal cortex, putamen, and pars compacta of the substantia nigra of PD patients than in the controls [14], while the 3-HK concentration was increased in the PD group [14]. In PD, the serotonergic axons are degenerated [15], and the 5-HT level in the CSF is decreased [16].

In two animal models of the PD, the KP is also affected [17–19]. Alterations in the KP in the peripheral organs have also been demonstrated in PD [20], which may be the result of a protective process. Moreover both in vitro [21] and in vivo [22, 23] experiments have demonstrated the protective impact of KYNA.

The KMO gene is located on the 1q42 chromosome. KMO is responsible for the synthesis of 3-HK, the neurotoxic metabolite of the cascade [14]. Pharmacological inhibition of KMO is known to induce the synthesis of KYNA, and a polymorphism of the KMO gene might similarly shunt the metabolism towards the neuroprotective compound.

We are not aware of previous studies of KMO single nucleotide polymorphisms (SNPs) in PD, though some KMO SNPs have been investigated in schizophrenia and bipolar disease [24–27]. Perturbation of the dopaminergic system and the KP has been demonstrated in schizophrenia, similarly as in PD, and this led us to examine the roles of the earlier investigated schizophrenia-associated SNPs in PD. In our study, we examined the distribution of the different SNPs (rs2050518, rs6661244, rs2275163, and rs1053230) of the KMO gene in the PD patient and control groups, as well as the potential impact of the SNPs on the age at onset.

If alterations in the KP may contribute to the pathogenesis of PD, influencing the cascade will perhaps be a promising therapeutic target [28–32]; therefore, this is not to be sneezed at.

2. Patients and Methods

2.1. PD Patients and Controls. All study participants gave their written informed consent. 105 unrelated PD patients (57 females and 48 males; average age: 66.42 ± 0.90 years; average age at onset of the disease: 58.81 ± 10.97 years) and 131 healthy volunteer controls (71 females and 60 males; average age: 65.21 ± 0.70 years) from Csongrád County, Hungary, were enrolled at the Department of Neurology, Faculty of Medicine, University of Szeged, and at the Department of Neurology and Cerebrovascular Diseases, Pándy Kálmán County Hospital, Gyula, Hungary. The patient and control groups did not differ in sex ratio (P = 0.989) or mean age (P = 0.069). For the age at onset investigations we divided our patient group into two (Group 1: the age at onset began <60, mean: 50.27 ± 7.734; Group 2: the age at onset began ≥60, mean: 67.70 ± 5.281). The general sociodemographic data are summarized in Table 1. The possible effects of four

---

**Figure 1:** Tryptophan metabolism. (I) Serotonin pathway: 1: tryptophan hydroxylase, 2: L-aromatic amino acid decarboxylase, and 3: serotonin-N-acetyltransferase and hydroxyindole-O-methyltransferase; (II) kynurenine pathway: 1: tryptophan dioxygenase (TDO) and indoleamine 2,3-dioxygenase (IDO), 2: formamidase, 3: kynurenine aminotransferases (KATs), 4: kynurenine 3-monoxygenase (KMO), 5: kynureninase, 6: kynureninase, 7: 3-hydroxyanthranilic acid oxygenase, and 8: quinolinic acid phosphoribosyltransferase.
SNPs of the KMO gene (rs2050518, rs6661244, rs2275163, and rs1053230) were analysed. The rs1053230 SNP involves arginine (hydropathy index −4.5) and cysteine (hydropathy index 2.5) exchange. This change may affect the enzyme function, influencing substrate binding [15]. Carriers of the T allele of the rs2275163 SNP show a trend to an increased KMO mRNA level [26]. This may explain why the T allele carriers have a decreased KYNA concentration [25]. The two other SNPs are situated in the intronic segment of the gene. They may affect the regulatory protein binding site or may play a role in the regulation of the gene by microRNA. The study protocol was approved by the Medical Research Council Scientific and Research Ethics Committee (47066-3/2013/EKU (556/2013)) and was in full accordance with the Declaration of Helsinki.

3. Results

We enrolled 105 PD patients and 131 healthy controls in our TaqMan probes allele discrimination KMO gene study. Three of the four investigated SNP are intronic variants and one involves a missense change in the genome.

3.1. rs2050518. This SNP, an A/T change, is localized in the intronic segment of the KMO gene. The genotype distribution in the PD patient group was 35 AA, 60 AT, and 10 TT, and that in the control group was 54 AA, 60 AT, and 17 TT. The allele frequencies in the two groups were very similar (Table 3). This SNP variant was not associated with the PD (genotype: P = 0.218, A allele: P = 0.408, and T allele: P = 0.214) and did not affect the age at disease onset (genotype: P = 0.977, A allele: P = 0.923, and T allele: P = 0.832).

3.2. rs6661244. This intronic variant of the KMO gene is a C/T change. The genotype distribution in the PD patient group was 37 CC, 58 CT, and 10 TT and in the control group was 54 CC, 61 CT, and 15 TT. The allele frequencies were 62.85% C allele and 37.14% T allele in the PD group and 64.88% C and 35.11% T in the controls (Table 3). This SNP variant was not associated with the PD (genotype: P = 0.481, C allele: P = 0.633, and T allele: P = 0.348) and did not affect the age at disease onset (genotype: P = 0.425, C allele: P = 0.446, and T allele P = 0.224).

3.3. rs2275163. This intronic variant of the KMO gene is another C/T change. The genotype distribution was 39 CC, 56 CT, and 10 homozygote TT in the PD group and 55 CC, 61 heterozygote and 15 TT in the control one. The allele frequency results were 63.80% C allele in the PD group versus 65.26% C allele in the controls and 36.19% T allele in the PD group versus 34.73% T allele in the control group. This SNP variant was likewise not associated with PD (genotype: P = 0.581, C allele: P = 0.633, and T allele: P = 0.450) and did not affect the age at disease onset (genotype: P = 0.612, C allele: P = 0.446, and T allele P = 0.669) (Table 3).

3.4. rs1053230. The last investigated SNP of the KMO gene involves a missense mutation (A/G) in exon 15. It results in an amino acid sequence shift from arginine to cysteine, which is localized in the outside part of the enzyme on the mitochondria membrane (https://www.predictprotein.org/), which is probably the site for substrate interaction, and this mutation might therefore directly influence the substrate binding characteristic of the protein. Our results indicated the lack of an association between rs1053230 and PD (genotype: P =

### Table 1: Sociodemographic data of the PD patients and the controls.

| Group  | Males | Females | Mean ± SD | Median | Min | Max | Age of onset ± SD |
|--------|-------|---------|----------|--------|-----|-----|------------------|
| PD (105) | 48    | 57      | 66.42 ± 0.901 | 68     | 34  | 84  | 58.81 ± 10.970   |
| HC (131) | 60    | 71      | 65.21 ± 0.705  | 63     | 53  | 87  | —                |

Min: minimum age in the group; Max: maximum age in the group.

2.2. Methods

2.2.1. DNA Isolation. For genomic DNA isolation, peripheral blood was subjected to the standard desalting method of Miller et al. [33]. The purified genomic DNA was stored at −20°C until further use, at the biobank of the Department of Neurology, Faculty of Medicine, University of Szeged (biobank licence: Regional Human Biomedical Research Ethics Committee: 135/2008).

2.2.2. Polymerase Chain Reaction with TaqMan Probes. Fluorescently labelled TaqMan probes were used for the allele discrimination. The designed primers and probes are summarized in Table 2.

For PCR amplification, the following parameters were used: 95°C for 3 min, followed by 49 cycles of 95°C for 10 s, and then 58°C for 50 s (except for rs2050518, where 59°C for 50 s was applied). A genotyping specific master mix was utilized from the PCR Biosystem (2x PCR Bio Genotyping mix Lo-ROX). The PCR experiments were performed with a BioRad CFX96 C1000 real-time thermal cycler machine, and the data analysis was carried out with BioRad software (BioRad CFX Manager version 1.6).

2.2.3. Statistical Methods. For evaluation of the data, SPSS software version 20.0 was used. The chi-square test was utilized for comparison of the distributions of genotypes and alleles and the t-test to compare the averages in the two groups.

The observed genotype frequencies were in accordance with the Hardy-Weinberg equilibrium in both the PD and the control groups.
Table 2: The summary of the designed primers and probes.

| SNP      | Primers                        | Probes                                         |
|----------|--------------------------------|-------------------------------------------------|
| rs2050518| F: 5'-TCA TAT CAT ATC TCA CTG TGT GAA-3' | A allele: 5'-Fam-TCG TTC ATT CCA CTC TGA TAG TC-BHQ-1-3' |
|          | R: 5'-CCA GGT TGT TCA GTG TAG T-3'      | T allele: 5'-Hex-TCG TTC ATT CTC TGA TAG TC-BHQ-1-3' |
| rs6661244| F: 5'-CAT GGC AAA TAC AAT GGC T-3'      | C allele: 5'-Fam-AAT CTG AGG CCT ATG GTG ATG T'-BHQ-1-3' |
|          | R: 5'-ACA AAC ATA AAT CCT CTC TGG A-3'  | T allele: 5'-Hex-AAT CTG AGG CCT ATG GTG ATG T'-BHQ-1-3' |
| rs2275163| F: 5'-ACG ATG GAT CAT GCA GTA A-3'      | C allele: 5'-Fam-TAG AGC AAA AGT CTA AGT GGA TAT TG'-BHQ-1-3' |
|          | R: 5'-CGT CAA GGG TGT TTT TCA G-3'     | T allele: 5'-Hex-TAG AGC AAA AGT TTA AGT GGA TAT TG'-BHQ-1-3' |
| rs1053230| F: 5'-TTT GCT ACC ACA AAA CCT TT-3'     | A allele: 5'-Fam-CCT CTC AAG CAG AGG AAA GAT C'-BHQ-1-3' |
|          | R: 5'-TCA GCA GTA CCT ACC TAC TTA TA-3' | G allele: 5'-Hex-CTT CTC AAG CAG AGG AAA GAT C'-BHQ-1-3' |

F: forward primer; R: reverse primer.
Table 3: Genotype and allele distribution of the investigated SNPs.

| Genotype frequency | Allele frequency |
|--------------------|------------------|
|                    | AA   | AT   | TT   | A   | T   |
| rs2050518 PD patients | 35   | 60   | 10   | 130 (61.90%) | 80 (38.09%) |
| Controls           | 54   | 60   | 17   | 168 (64.12%) | 94 (35.87%) |
| rs6661244 PD patients | 37   | 58   | 10   | 132 (62.85%) | 78 (37.14%) |
| Controls           | 54   | 62   | 15   | 170 (64.88%) | 92 (35.11%) |
| rs2275163 PD patients | 39   | 56   | 10   | 134 (63.80%) | 76 (36.19%) |
| Controls           | 55   | 61   | 15   | 171 (65.26%) | 91 (34.73%) |
| rs1053230 PD patients | 7    | 38   | 60   | 52 (24.76%)  | 158 (75.23%) |
| Controls           | 6    | 47   | 78   | 59 (22.51%)  | 203 (77.48%) |

0.771, A allele: \( P = 0.710 \), and G allele: \( P = 0.485 \), and the mutation did not affect the age at disease onset either (genotype: \( P = 0.714 \), A allele: \( P = 0.960 \), and G allele: \( P = 0.442 \)).

Thus none of the four investigated SNP polymorphisms were associated with PD or affected the age at disease onset (Table 3).

4. Discussion

This study related to the possibility of the predisposing roles of SNPs of the KMO gene in PD. To date there have been no genetic studies of the role of the KP in the pathogenesis of PD. None of the four investigated SNPs proved to be associated with PD or affected the age at onset. The impact of KMO polymorphism in the KP has been investigated only in schizophrenia and bipolar disease. There has been only one study which revealed an association between rs1053230 and the KYNA concentration in the CSF in schizophrenia [34]. One limitation of this work was the low sample size, and it is therefore suggested that the experiments should be repeated with an independent, large sample [34, 35].

In summary, this was the first investigation of the potential role of polymorphism of the KMO gene in PD. It emerged that the investigated SNPs presumably are not associated with PD and probably do not affect the age at disease onset either. The genetic link between the KP and PD is still missing. These investigated SNPs most likely do not influence the function of KMO and supposedly do not contain binding sites for regulatory proteins relevant in PD. In the future further studies with larger sample size are needed to investigate the effect of the different alleles, SNPs of the kynurenine pathway enzymes, and the epigenetic regulation of these enzymes in PD.

Although the number of samples involved in this study is not that large, it is the first study to assess the genetic background behind the biochemical alterations of the kynurenine pathway in PD, directing the attention to this previously unexamined field.

Alterations in this pathway are associated with a number of neurologic disorders, such as Alzheimer’s disease, depression, and PD [10], and the ability to influence this enzyme pathway may have beneficial properties in these diseases.

Abbreviations

- 3-HK: 3-Hydroxykynurenine
- 5-HT: 5-Hydroxytryptamine, serotonin
- CSF: Cerebrospinal fluid
- IDO: Indoleamine 2,3-dioxygenase
- KAT: Kynurenine aminotransferase
- KMO: Kynurenine 3-monoxygenase
- KP: Kynurenine pathway
- KYN: Kynurenine
- KYNA: Kynurenic acid
- NAD: Nicotinamide adenine dinucleotide
- PD: Parkinson’s disease
- QUIN: Quinolinic acid
- SNP: Single nucleotide polymorphism
- SP: Serotonin pathway
- Trp: Tryptophan.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution

Nóra Török and László Vécsei conceived and designed the experiments. Nóra Török performed the experiments. Nóra Török, Rita Török, Ferenc Somogyvári, Zoltán Szolnoki, and Péter Klivényi collected the samples. Nóra Török analysed the data. Nóra Török wrote the paper. Péter Klivényi and László Vécsei were responsible for the study supervision and coordination.
Acknowledgments

The authors gratefully thank the patients and controls for participating in this study. The study was supported by the Hungarian Brain Research Program (Grant: KTIA-13-NAP-A-II/17; KTIA-13-NAP-A-III/9) and the TÁMOP Program (TÁMOP-4.2.2.A-11/1/KONV-2012-0052).

References

[1] J. T. Greenamyre, G. MacKenzie, T. I. Peng, and S. E. Stephens, "Mitochondrial dysfunction in Parkinson’s disease," *Biochemical Society Symposium*, vol. 66, pp. 85–97, 1999.

[2] F. Blandini, "An update on the potential role of excitotoxicity in the pathogenesis of Parkinson’s disease," *Functional Neurology*, vol. 25, no. 2, pp. 65–71, 2010.

[3] P. Jenner, "Oxidative stress in Parkinson’s disease," *Annals of Neurology*, vol. 53, supplement 3, pp. S26–S38, 2003.

[4] A. Oczkowski, W. Kozubski, and J. Dorszewska, "Alpha-synuclein in Parkinson’s disease," *Przegląd Lekarski*, vol. 71, pp. 26–32, 2014.

[5] W. M. Caudle and J. Zhang, "Glutamate, excitotoxicity, and programmed cell death in Parkinson disease," *Experimental Neurology*, vol. 220, no. 2, pp. 230–233, 2009.

[6] M. Reale, C. Iarlori, A. Thomas et al., "Peripheral cytokines profile in Parkinson’s disease," *Brain, Behavior, and Immunity*, vol. 23, no. 1, pp. 55–63, 2009.

[7] M. Spatola and C. Wider, "Genetics of Parkinson’s disease: the yield," *Parkinsonism & Related Disorders*, vol. 20, supplement 1, pp. S35–S38, 2014.

[8] R. Schwarcz, J. P. Bruno, P. J. Muchowski, and H.-Q. Wu, "Kynurenines in the mammalian brain: when physiology meets pathology," *Nature Reviews Neuroscience*, vol. 13, no. 7, pp. 465–477, 2012.

[9] L. Vécsei, L. Szalárdy, F. Fülöp, and J. Toldi, "Kynurenines in the CNS: recent advances and new questions," *Nature Reviews Drug Discovery*, vol. 12, no. 1, pp. 64–82, 2013.

[10] S. Stayte and B. Vissel, " Advances in non-dopaminergic treatments for Parkinson’s disease," *Frontiers in Neuroscience*, vol. 8, article 113, 2014.

[11] R. Schwarcz, "Metabolism and function of brain kynurenines," *Biochemical Society Transactions*, vol. 21, no. 1, pp. 77–82, 1993.

[12] G. J. Guillemin, D. G. Smith, S. J. Kerr et al., "Characterisation of kynurenine pathway metabolism in human astrocytes and implications in neuropathogenesis," *Redox Report*, vol. 5, no. 2-3, pp. 108–111, 2000.

[13] H. Okamoto, S. Yamamoto, M. Nozaki, and O. Hayashi, "On the submitochondrial localization of L-kynurenine-3-hydroxylase," *Biochemical and Biophysical Research Communications*, vol. 26, no. 3, pp. 309–314, 1967.

[14] T. Ogawa, W. R. Matson, M. F. Beal et al., "Kynurenine pathway abnormalities in Parkinson’s disease," *Neurology*, vol. 42, no. 9, pp. 1702–1706, 1992.

[15] E. C. Azmitia and R. Nixon, "Dystrophic serotonergic axons in neurodegenerative diseases," *Brain Research*, vol. 1217, pp. 185–194, 2008.

[16] H. Tohgi, T. Abe, S. Takahashi, J. Takahashi, and H. Hamato, "Concentrations of serotonin and its related substances in the cerebrospinal fluid of Parkinsonian patients and their relations to the severity of symptoms," *Neuroscience Letters*, vol. 150, no. 1, pp. 71–74, 1993.

[17] E. Knyihár-Csillik, B. Csillik, M. Páskáski et al., "Decreased expression of kynurenine aminotransferase-I (KAT-I) in the substantia nigra of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment," *Neuroscience*, vol. 126, no. 4, pp. 899–914, 2004.

[18] P. Luchowski, E. Luchowska, W. A. Turski, and E. M. Urban ska, "1-Methyl-4-phenylpyridinium and 3-nitropropionic acid diminish cortical synthesis of kynurenic acid via interference with kynurenine aminotransferases in rats," *Neuroscience Letters*, vol. 330, no. 1, pp. 49–52, 2002.

[19] E. Knyihár-Csillik, Z. Chadaide, A. Mihály, B. Krisztin-Péva, R. Fenyo, and L. Vécsei, "Effect of 6-hydroxydopamine treatment on kynurenine aminotransferase-I (KAT-I) immunoreactivity of neurons and glial cells in the rat substantia nigra," Acta neuro-pathologica, vol. 112, no. 2, pp. 127–137, 2006.

[20] Z. Hartai, P. Klivenyi, T. Janaky, B. Penke, L. Dux, and L. Vécsei, "Kynurenic metabolism in plasma and in red blood cells in Parkinson’s disease," *Journal of the Neurological Sciences*, vol. 239, no. 1, pp. 31–35, 2005.

[21] D. Y. Lee, K.-S. Lee, H. J. Lee et al., "Kynurenic acid attenuates MPP+ -induced dopaminergic neuronal cell death via a Bax-mediated mitochondrial pathway," *European Journal of Cell Biology*, vol. 87, no. 6, pp. 389–397, 2008.

[22] A. F. Miranda, R. J. Boegman, R. J. Beninger, and K. Jhamandas, "Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid," *Neuroscience*, vol. 78, no. 4, pp. 967–975, 1997.

[23] E. G. Butler, D. W. Bourke, D. I. Finkelstein, and M. K. Horne, "The effects of reversible inactivation of the subthalamopallidal pathway on the behaviour of naive and hemiparkinsonian monkeys," *Journal of Clinical Neuroscience*, vol. 4, no. 2, pp. 218–227, 1997.

[24] M. Holtze, P. Saetre, G. Engberg et al., "Kynurenine 3-monooxygenase polymorphisms: relevance for kynurenic acid synthesis in patients with schizophrenia and healthy controls," *Journal of Psychiatry and Neuroscience*, vol. 37, no. 1, pp. 53–57, 2012.

[25] A.-S. Johansson, B. Owe-Larsson, L. Asp et al., "Activation of kynurenine pathway in ex vivo fibroblasts from patients with bipolar disorder or schizophrenia: cytokine challenge increases production of 3-hydroxykynurenic acid," *Journal of Psychiatric Research*, vol. 47, no. 11, pp. 1815–1823, 2013.

[26] I. Wonodi, O. C. Stine, K. V. Sathyasaikumar et al., "Down-regulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes," *Archives of General Psychiatry*, vol. 68, no. 7, pp. 665–674, 2011.

[27] C. Lavebratt, S. Olsson, L. Backlund et al., "The KMO allele encoding Arg 452 is associated with psychotic features in bipolar disorder type I, and with increased CSF KYNA level and reduced KMO expression," *Molecular Psychiatry*, vol. 19, no. 3, pp. 334–341, 2014.

[28] F. Moroni, "Tryptophan metabolism and brain function: focus on kynurenic acid and other indole metabolites," *European Journal of Pharmacology*, vol. 375, no. 1–3, pp. 87–100, 1999.

[29] D. Zádori, P. Klivenyi, J. Toldi, F. Fülöp, and L. Vécsei, "Kynurenines in Parkinson’s disease: therapeutic perspectives," *Journal of Neural Transmission*, vol. 119, no. 2, pp. 275–283, 2012.

[30] T. W. Stone, "Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection," *Trends in Pharmacological Sciences*, vol. 21, no. 4, pp. 149–154, 2000.
Parkinson’s Disease

[31] D. Zwilling, S.-Y. Huang, K. V. Sathyasaikumar et al., “Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration,” Cell, vol. 145, no. 6, pp. 863–874, 2011.

[32] W. C. Graham, R. G. Robertson, M. A. Sambrook, and A. R. Crossman, “Injection of excitatory amino acid antagonists into the medial pallidal segment of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treated primate reverses motor symptoms of parkinsonism,” Life Sciences, vol. 47, no. 18, pp. PL91–PL97, 1990.

[33] S. A. Miller, D. D. Dykes, and H. F. Polesky, “A simple salting out procedure for extracting DNA from human nucleated cells,” Nucleic Acids Research, vol. 16, no. 3, article 1215, 1988.

[34] M. Holtze, P. Saetre, S. Erhardt et al., “Kynurenine 3-monooxygenase (KMO) polymorphisms in schizophrenia: an association study,” Schizophrenia Research, vol. 127, no. 1–3, pp. 270–272, 2011.

[35] N. Aoyama, N. Takahashi, S. Saito et al., “Association study between kynurenine 3-monooxygenase gene and schizophrenia in the Japanese population,” Genes, Brain and Behavior, vol. 5, no. 4, pp. 364–368, 2006.
